Related Experiment Videos

Targeting insulin resistance and beta-cell dysfunction: the role of thiazolidinediones

S Del Prato1, P Marchetti

  • 1Section of Diabetes and Metabolic Diseases, Department of Endocrinology and Metabolism, Ospedale Cisanello, Pisa, Italy. delprato@immr.med.unipi.it

Diabetes Technology & Therapeutics
|January 5, 2005
PubMed

Insights

Thiazolidinediones improve insulin sensitivity and beta-cell function, targeting key defects in type 2 diabetes. Studies show these agents can delay disease progression, offering a preventative approach.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Insulin resistance and beta-cell dysfunction are central to type 2 diabetes development.
  • Glucotoxicity and lipotoxicity are key factors influencing these defects.
  • Understanding molecular mechanisms is crucial for disease prevention.

Purpose of the Study:

  • To evaluate thiazolidinediones as a strategy for type 2 diabetes prevention.
  • To assess the impact of thiazolidinediones on insulin sensitivity and beta-cell function.
  • To review evidence on delaying disease progression with thiazolidinediones.

Main Methods:

  • Review of clinical studies and prospective trials, including TRIPOD and DREAM.
  • Analysis of thiazolidinedione efficacy in monotherapy and combination therapy.
  • Assessment of effects on hyperglycemia, insulin sensitivity, and beta-cell function.

Main Results:

  • Thiazolidinediones effectively improve insulin sensitivity and beta-cell function.
  • Evidence suggests thiazolidinediones can delay the progression to type 2 diabetes.
  • Ongoing studies evaluate long-term metabolic and disease progression effects.

Conclusions:

  • Thiazolidinediones represent a promising therapeutic class for type 2 diabetes primary prevention.
  • Targeting fundamental defects offers a new paradigm in diabetes management.
  • Further research is evaluating long-term benefits and safety profiles.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...